APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia AAV Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hemophilia AAV Gene Therapy Market Analysis and Forecast 2026-2032

26 December 2025192 pages

Choose your research edition.

Industry ResearchHemophilia AAV Gene Therapy Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia AAV Gene Therapy Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Hemophilia AAV Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia AAV Gene Therapy Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia AAV Gene Therapy Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Hemophilia AAV Gene Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hemophilia AAV Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hemophilia AAV Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hemophilia AAV Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hemophilia AAV Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hemophilia AAV Gene Therapy include Pfizer, CSL/uniQure (Hemgenix&Glybera) and BioMarin (Roctavian), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hemophilia AAV Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hemophilia AAV Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Hemophilia AAV Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hemophilia AAV Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hemophilia AAV Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hemophilia AAV Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.

Hemophilia AAV Gene Therapy Segment by Company

Pfizer

CSL/uniQure (Hemgenix&Glybera)

BioMarin (Roctavian)

Hemophilia AAV Gene Therapy Segment by Type

AVV5 Vector

AAVrh74 Vector

Hemophilia AAV Gene Therapy Segment by Application

Hemophilia A

Hemophilia B

Hemophilia AAV Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia AAV Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia AAV Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia AAV Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hemophilia AAV Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hemophilia AAV Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia AAV Gene Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hemophilia AAV Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. AVV5 Vector Major Player Table 3. AAVrh74 Vector Major Player Table 4. Global Hemophilia AAV Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hemophilia A Major Player Table 6. Hemophilia B Major Player Table 7. Hemophilia AAV Gene Therapy Industry Trends Table 8. Hemophilia AAV Gene Therapy Industry Drivers Table 9. Hemophilia AAV Gene Therapy Industry Opportunities and Challenges Table 10. Hemophilia AAV Gene Therapy Industry Restraints Table 11. Global Hemophilia AAV Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Hemophilia AAV Gene Therapy Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Hemophilia AAV Gene Therapy Market Share by Region (2021-2026) Table 14. Global Hemophilia AAV Gene Therapy Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Hemophilia AAV Gene Therapy Market Share by Region (2027-2032) Table 16. Global Hemophilia AAV Gene Therapy Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Hemophilia AAV Gene Therapy Revenue Market Share by Players (2021-2026) Table 18. Global Hemophilia AAV Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Hemophilia AAV Gene Therapy Key Players Headquarters & Area Served Table 20. Global Hemophilia AAV Gene Therapy Players, Product Type & Application Table 21. Global Hemophilia AAV Gene Therapy Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Hemophilia AAV Gene Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Hemophilia AAV Gene Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hemophilia AAV Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Hemophilia AAV Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Hemophilia AAV Gene Therapy Revenue Market Share by Type (2021-2026) Table 28. Global Hemophilia AAV Gene Therapy Revenue Market Share by Type (2027-2032) Table 29. Global Hemophilia AAV Gene Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Hemophilia AAV Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Hemophilia AAV Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Hemophilia AAV Gene Therapy Revenue Market Share by Application (2021-2026) Table 33. Global Hemophilia AAV Gene Therapy Revenue Market Share by Application (2027-2032) Table 34. Pfizer Company Information Table 35. Pfizer Business Overview Table 36. Pfizer Hemophilia AAV Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Pfizer Hemophilia AAV Gene Therapy Product Portfolio Table 38. Pfizer Recent Development Table 39. CSL/uniQure (Hemgenix&Glybera) Company Information Table 40. CSL/uniQure (Hemgenix&Glybera) Business Overview Table 41. CSL/uniQure (Hemgenix&Glybera) Hemophilia AAV Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. CSL/uniQure (Hemgenix&Glybera) Hemophilia AAV Gene Therapy Product Portfolio Table 43. CSL/uniQure (Hemgenix&Glybera) Recent Development Table 44. BioMarin (Roctavian) Company Information Table 45. BioMarin (Roctavian) Business Overview Table 46. BioMarin (Roctavian) Hemophilia AAV Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. BioMarin (Roctavian) Hemophilia AAV Gene Therapy Product Portfolio Table 48. BioMarin (Roctavian) Recent Development Table 49. North America Hemophilia AAV Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 50. North America Hemophilia AAV Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 51. North America Hemophilia AAV Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 52. North America Hemophilia AAV Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 53. North America Hemophilia AAV Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 54. North America Hemophilia AAV Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 55. North America Hemophilia AAV Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 56. Europe Hemophilia AAV Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 57. Europe Hemophilia AAV Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 58. Europe Hemophilia AAV Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 59. Europe Hemophilia AAV Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 60. Europe Hemophilia AAV Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 61. Europe Hemophilia AAV Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 62. Europe Hemophilia AAV Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 63. China Hemophilia AAV Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 64. China Hemophilia AAV Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 65. China Hemophilia AAV Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 66. China Hemophilia AAV Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 67. Asia Hemophilia AAV Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 68. Asia Hemophilia AAV Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 69. Asia Hemophilia AAV Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 70. Asia Hemophilia AAV Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 71. Asia Hemophilia AAV Gene Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 72. Asia Hemophilia AAV Gene Therapy Revenue by Region (US$ Million) & (2021-2026) Table 73. Asia Hemophilia AAV Gene Therapy Revenue by Region (US$ Million) & (2027-2032) Table 74. SAMEA Hemophilia AAV Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 75. SAMEA Hemophilia AAV Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 76. SAMEA Hemophilia AAV Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 77. SAMEA Hemophilia AAV Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 78. SAMEA Hemophilia AAV Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. SAMEA Hemophilia AAV Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 80. SAMEA Hemophilia AAV Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Hemophilia AAV Gene Therapy Image Figure 2. Global Hemophilia AAV Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia AAV Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. AVV5 Vector Image Figure 5. AAVrh74 Vector Image Figure 6. Global Hemophilia AAV Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Hemophilia AAV Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hemophilia A Image Figure 9. Hemophilia B Image Figure 10. Global Hemophilia AAV Gene Therapy Market Size (US$ Million) & (2021-2032) Figure 11. Global Hemophilia AAV Gene Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Hemophilia AAV Gene Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Hemophilia AAV Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Hemophilia AAV Gene Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Hemophilia AAV Gene Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Hemophilia AAV Gene Therapy Revenue Market Share by Type (2021-2032) Figure 18. Global Hemophilia AAV Gene Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Hemophilia AAV Gene Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Hemophilia AAV Gene Therapy Revenue Market Share by Application (2021-2032) Figure 21. North America Hemophilia AAV Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032) Figure 23. North America Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032) Figure 24. North America Hemophilia AAV Gene Therapy Revenue Share by Country (2021-2032) Figure 25. United States Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Hemophilia AAV Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032) Figure 30. Europe Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032) Figure 31. Europe Hemophilia AAV Gene Therapy Revenue Share by Country (2021-2032) Figure 32. Germany Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Hemophilia AAV Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032) Figure 42. China Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032) Figure 43. Asia Hemophilia AAV Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032) Figure 45. Asia Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032) Figure 46. Asia Hemophilia AAV Gene Therapy Revenue Share by Region (2021-2032) Figure 47. Japan Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Hemophilia AAV Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032) Figure 55. SAMEA Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032) Figure 56. SAMEA Hemophilia AAV Gene Therapy Revenue Share by Country (2021-2032) Figure 57. Brazil Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Hemophilia AAV Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • AVV5 Vector
  • AAVrh74 Vector
Applications
  • Hemophilia A
  • Hemophilia B
Companies covered
  • Pfizer
  • CSL/uniQure (Hemgenix&Glybera)
  • BioMarin (Roctavian)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hemophilia AAV Gene Therapy Market by Type
  3. 1.2.1 Global Hemophilia AAV Gene Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 AVV5 Vector
  5. 1.2.3 AAVrh74 Vector
  6. 1.3 Hemophilia AAV Gene Therapy Market by Application
  7. 1.3.1 Global Hemophilia AAV Gene Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hemophilia A
  9. 1.3.3 Hemophilia B
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Hemophilia AAV Gene Therapy Market Dynamics
  1. 2.1 Hemophilia AAV Gene Therapy Industry Trends
  2. 2.2 Hemophilia AAV Gene Therapy Industry Drivers
  3. 2.3 Hemophilia AAV Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Hemophilia AAV Gene Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hemophilia AAV Gene Therapy Market Perspective (2021-2032)
  2. 3.2 Global Hemophilia AAV Gene Therapy Growth Trends by Region
  3. 3.2.1 Global Hemophilia AAV Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hemophilia AAV Gene Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Hemophilia AAV Gene Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hemophilia AAV Gene Therapy Revenue by Players
  2. 4.1.1 Global Hemophilia AAV Gene Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Hemophilia AAV Gene Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hemophilia AAV Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hemophilia AAV Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hemophilia AAV Gene Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Hemophilia AAV Gene Therapy Players, Product Type & Application
  8. 4.5 Global Hemophilia AAV Gene Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hemophilia AAV Gene Therapy Market CR5 and HHI
  11. 4.6.3 2025 Hemophilia AAV Gene Therapy Tier 1, Tier 2, and Tier 3
5 Hemophilia AAV Gene Therapy Market Size by Type
  1. 5.1 Global Hemophilia AAV Gene Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hemophilia AAV Gene Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Hemophilia AAV Gene Therapy Revenue Market Share by Type (2021-2032)
6 Hemophilia AAV Gene Therapy Market Size by Application
  1. 6.1 Global Hemophilia AAV Gene Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hemophilia AAV Gene Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Hemophilia AAV Gene Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Hemophilia AAV Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Hemophilia AAV Gene Therapy Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 CSL/uniQure (Hemgenix&Glybera)
  8. 7.2.1 CSL/uniQure (Hemgenix&Glybera) Company Information
  9. 7.2.2 CSL/uniQure (Hemgenix&Glybera) Business Overview
  10. 7.2.3 CSL/uniQure (Hemgenix&Glybera) Hemophilia AAV Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CSL/uniQure (Hemgenix&Glybera) Hemophilia AAV Gene Therapy Product Portfolio
  12. 7.2.5 CSL/uniQure (Hemgenix&Glybera) Recent Developments
  13. 7.3 BioMarin (Roctavian)
  14. 7.3.1 BioMarin (Roctavian) Company Information
  15. 7.3.2 BioMarin (Roctavian) Business Overview
  16. 7.3.3 BioMarin (Roctavian) Hemophilia AAV Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 BioMarin (Roctavian) Hemophilia AAV Gene Therapy Product Portfolio
  18. 7.3.5 BioMarin (Roctavian) Recent Developments
8 North America
  1. 8.1 North America Hemophilia AAV Gene Therapy Revenue (2021-2032)
  2. 8.2 North America Hemophilia AAV Gene Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Hemophilia AAV Gene Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Hemophilia AAV Gene Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Hemophilia AAV Gene Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Hemophilia AAV Gene Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Hemophilia AAV Gene Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Hemophilia AAV Gene Therapy Revenue by Country
  11. 8.6.1 North America Hemophilia AAV Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hemophilia AAV Gene Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Hemophilia AAV Gene Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hemophilia AAV Gene Therapy Revenue (2021-2032)
  2. 9.2 Europe Hemophilia AAV Gene Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hemophilia AAV Gene Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hemophilia AAV Gene Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hemophilia AAV Gene Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hemophilia AAV Gene Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hemophilia AAV Gene Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hemophilia AAV Gene Therapy Revenue by Country
  11. 9.6.1 Europe Hemophilia AAV Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hemophilia AAV Gene Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hemophilia AAV Gene Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hemophilia AAV Gene Therapy Revenue (2021-2032)
  2. 10.2 China Hemophilia AAV Gene Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Hemophilia AAV Gene Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Hemophilia AAV Gene Therapy Revenue by Type (2027-2032)
  5. 10.3 China Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Hemophilia AAV Gene Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Hemophilia AAV Gene Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Hemophilia AAV Gene Therapy Revenue by Application (2027-2032)
  9. 10.5 China Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hemophilia AAV Gene Therapy Revenue (2021-2032)
  2. 11.2 Asia Hemophilia AAV Gene Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hemophilia AAV Gene Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hemophilia AAV Gene Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hemophilia AAV Gene Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hemophilia AAV Gene Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hemophilia AAV Gene Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hemophilia AAV Gene Therapy Revenue by Country
  11. 11.6.1 Asia Hemophilia AAV Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hemophilia AAV Gene Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hemophilia AAV Gene Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hemophilia AAV Gene Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Hemophilia AAV Gene Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hemophilia AAV Gene Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hemophilia AAV Gene Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hemophilia AAV Gene Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hemophilia AAV Gene Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hemophilia AAV Gene Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hemophilia AAV Gene Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hemophilia AAV Gene Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hemophilia AAV Gene Therapy Revenue by Country
  11. 12.6.1 SAMEA Hemophilia AAV Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hemophilia AAV Gene Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hemophilia AAV Gene Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst